Current Insights on Lipid-Based Nanosystems 2023
Lipid-based nanosystems, including solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages linked to these...
Bewaard in:
| Formaat: | Online |
|---|---|
| Taal: | Engels |
| Gepubliceerd in: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Onderwerpen: | |
| Online toegang: | ONIX_20240108_9783036598062_118 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|
| _version_ | 1869515955050119168 |
|---|---|
| collection | Directory of Open Access Books |
| description | Lipid-based nanosystems, including solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages linked to these systems are the ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small molecular weight or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has been further demonstrated through the delivery of vaccines, protection of cosmetic actives, or improvement in the moisturizing properties of cosmetic formulations. Currently, lipid-based nanosystems are well established, and there are already different commercially approved formulations for different human disorders. This success has actually paved the way to diversifying the pipeline of development, upon addressing unmet medical needs for several indications, such as cancer; neurological disorders; and autoimmune, genetic, and infectious diseases. This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. |
| format | Online |
| id | doab-20.500.12854ir-132459 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1324592024-04-09T23:16:25Z Current Insights on Lipid-Based Nanosystems 2023 Silva, Ana Catarina Moreira, João Sousa Lobo, José Manuel design of experiment porcine mucous membrane ophthalmic tissues permeation nanostructured lipid carriers gentiopicroside phospholipid complex self-nanoemulsion drug delivery system oral bioavailability pharmacokinetics antioxidants marine bio-waste bioactive compounds neurodegenerative diseases NLC solid lipid nanoparticles SLN intranasal administration nose-to-brain exosome drug loading exosomal delivery large-scale production lipid nanoparticles mucoadhesion ocular bioavailability surface modification liposomes baricitinib JAK-inhibitor transepidermal delivery skin permeation lipid NPs breast cancer siRNA delivery gene silencing personalized therapy bimatoprost central composite design glaucoma HET-CAM test solid lipid nanoparticles (SLNs) perillyl acid biodistribution empty lipid nanoparticles reactogenicity xenobiotics ionizable lipids isoniazid in vivo pharmacokinetics drug release profile histopathological toxicity mannosylation nanocarriers Chagas disease Trypanosoma cruzi in vivo assays quality by design plumbagin diabetes in vitro niosomes levosulpiride antidepressant acute toxicity in vivo imaging bioavailability cisplatin co-encapsulation mifepristone synergism gefitinib lipid surfactant stability breast cancer cell MTT assay anticancer n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues Lipid-based nanosystems, including solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages linked to these systems are the ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small molecular weight or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has been further demonstrated through the delivery of vaccines, protection of cosmetic actives, or improvement in the moisturizing properties of cosmetic formulations. Currently, lipid-based nanosystems are well established, and there are already different commercially approved formulations for different human disorders. This success has actually paved the way to diversifying the pipeline of development, upon addressing unmet medical needs for several indications, such as cancer; neurological disorders; and autoimmune, genetic, and infectious diseases. This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. 2024-01-08T14:55:20Z 2024-01-08T14:55:20Z 2023 book ONIX_20240108_9783036598062_118 9783036598062 9783036598055 https://directory.doabooks.org/handle/20.500.12854/132459 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/8499 https://mdpi.com/books/pdfview/book/8499 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9805-5 10.3390/books978-3-0365-9805-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036598062 9783036598055 340 Basel open access |
| spellingShingle | design of experiment porcine mucous membrane ophthalmic tissues permeation nanostructured lipid carriers gentiopicroside phospholipid complex self-nanoemulsion drug delivery system oral bioavailability pharmacokinetics antioxidants marine bio-waste bioactive compounds neurodegenerative diseases NLC solid lipid nanoparticles SLN intranasal administration nose-to-brain exosome drug loading exosomal delivery large-scale production lipid nanoparticles mucoadhesion ocular bioavailability surface modification liposomes baricitinib JAK-inhibitor transepidermal delivery skin permeation lipid NPs breast cancer siRNA delivery gene silencing personalized therapy bimatoprost central composite design glaucoma HET-CAM test solid lipid nanoparticles (SLNs) perillyl acid biodistribution empty lipid nanoparticles reactogenicity xenobiotics ionizable lipids isoniazid in vivo pharmacokinetics drug release profile histopathological toxicity mannosylation nanocarriers Chagas disease Trypanosoma cruzi in vivo assays quality by design plumbagin diabetes in vitro niosomes levosulpiride antidepressant acute toxicity in vivo imaging bioavailability cisplatin co-encapsulation mifepristone synergism gefitinib lipid surfactant stability breast cancer cell MTT assay anticancer n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues Current Insights on Lipid-Based Nanosystems 2023 |
| title | Current Insights on Lipid-Based Nanosystems 2023 |
| title_full | Current Insights on Lipid-Based Nanosystems 2023 |
| title_fullStr | Current Insights on Lipid-Based Nanosystems 2023 |
| title_full_unstemmed | Current Insights on Lipid-Based Nanosystems 2023 |
| title_short | Current Insights on Lipid-Based Nanosystems 2023 |
| title_sort | current insights on lipid based nanosystems 2023 |
| topic | design of experiment porcine mucous membrane ophthalmic tissues permeation nanostructured lipid carriers gentiopicroside phospholipid complex self-nanoemulsion drug delivery system oral bioavailability pharmacokinetics antioxidants marine bio-waste bioactive compounds neurodegenerative diseases NLC solid lipid nanoparticles SLN intranasal administration nose-to-brain exosome drug loading exosomal delivery large-scale production lipid nanoparticles mucoadhesion ocular bioavailability surface modification liposomes baricitinib JAK-inhibitor transepidermal delivery skin permeation lipid NPs breast cancer siRNA delivery gene silencing personalized therapy bimatoprost central composite design glaucoma HET-CAM test solid lipid nanoparticles (SLNs) perillyl acid biodistribution empty lipid nanoparticles reactogenicity xenobiotics ionizable lipids isoniazid in vivo pharmacokinetics drug release profile histopathological toxicity mannosylation nanocarriers Chagas disease Trypanosoma cruzi in vivo assays quality by design plumbagin diabetes in vitro niosomes levosulpiride antidepressant acute toxicity in vivo imaging bioavailability cisplatin co-encapsulation mifepristone synergism gefitinib lipid surfactant stability breast cancer cell MTT assay anticancer n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues |
| topic_facet | design of experiment porcine mucous membrane ophthalmic tissues permeation nanostructured lipid carriers gentiopicroside phospholipid complex self-nanoemulsion drug delivery system oral bioavailability pharmacokinetics antioxidants marine bio-waste bioactive compounds neurodegenerative diseases NLC solid lipid nanoparticles SLN intranasal administration nose-to-brain exosome drug loading exosomal delivery large-scale production lipid nanoparticles mucoadhesion ocular bioavailability surface modification liposomes baricitinib JAK-inhibitor transepidermal delivery skin permeation lipid NPs breast cancer siRNA delivery gene silencing personalized therapy bimatoprost central composite design glaucoma HET-CAM test solid lipid nanoparticles (SLNs) perillyl acid biodistribution empty lipid nanoparticles reactogenicity xenobiotics ionizable lipids isoniazid in vivo pharmacokinetics drug release profile histopathological toxicity mannosylation nanocarriers Chagas disease Trypanosoma cruzi in vivo assays quality by design plumbagin diabetes in vitro niosomes levosulpiride antidepressant acute toxicity in vivo imaging bioavailability cisplatin co-encapsulation mifepristone synergism gefitinib lipid surfactant stability breast cancer cell MTT assay anticancer n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues |
| url | ONIX_20240108_9783036598062_118 |